Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Kunika Saini, Smriti Sharma, Yousuf Aziz Khan
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
Vishal Mathur, Ozair Alam, Nadeem Siddiqui, et al.
Molecules (2023) Vol. 28, Iss. 15, pp. 5860-5860
Open Access | Times Cited: 30
A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: Synthetic approaches and clinical applications
Yuanyuan Guo, Jingyi Zhang, Jinfeng Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116185-116185
Closed Access | Times Cited: 15
Proline Analogues
Vladimir Kubyshkin, Marina Rubini
Chemical Reviews (2024) Vol. 124, Iss. 13, pp. 8130-8232
Closed Access | Times Cited: 10
Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications
Moein Ebrahimi, Hamid Ahmadieh, Mozhgan Rezaei Kanavi, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access | Times Cited: 1
Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention
Annunziata Nusca, Maria Pia Di Bitonto, A. Spanò, et al.
The American Journal of Cardiology (2025)
Closed Access | Times Cited: 1
Comparing the safety and effectiveness of imeglimin and vildagliptin as add-on therapies in type 2 diabetes patients: A record-based study
Shambo Samrat Samajdar, Rutul Gokalani, Kaushik Biswas, et al.
International Journal of Diabetes in Developing Countries (2025)
Closed Access | Times Cited: 1
Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies
Aditi Singh, Sucharita Shadangi, Pulkit Kr. Gupta, et al.
Comprehensive physiology (2025) Vol. 15, Iss. 1
Closed Access | Times Cited: 1
Recent advances and structure-activity relationship studies of DPP-4 inhibitors as anti-diabetic agents
Shipra Singhal, Vaishali M. Patil, Saroj Verma, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107277-107277
Closed Access | Times Cited: 8
Pharmacotherapeutic Considerations on Telomere Biology: The Positive Effect of Pharmacologically Active Substances on Telomere Length
Miruna-Maria Apetroaei, Persefoni Fragkiadaki, Bruno Ștefan Velescu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7694-7694
Open Access | Times Cited: 7
Vildagliptin ameliorates intrapulmonary vasodilatation and angiogenesis in chronic common bile duct ligation-induced hepatopulmonary syndrome in rat
Safwat A. Mangoura, Marwa A Ahmed, Nashwa Hamad, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 7, pp. 102408-102408
Closed Access | Times Cited: 6
Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications
Abhishek Satheesan, Janardanan Kumar, K.V. Leela, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 5, pp. 2753-2779
Closed Access | Times Cited: 6
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents
Yogita Dhas, Nupur Biswas, M R Divyalakshmi, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 6
Computational Modeling of the Interactions between DPP IV and Hemorphins
Priya Antony, Bincy Baby, Amie Jobe, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 3059-3059
Open Access | Times Cited: 5
The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside
Xiaofei Shen, Hongling Yang, Yang Yang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
A Review of Dipeptidyl Peptidase-4 (DPP-4) and its potential synthetic derivatives in the management of Diabetes Mellitus

Journal of Angiotherapy (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis
Yuxiang Lin, Guangyong Xu, Liangyu Li, et al.
Medicine (2024) Vol. 103, Iss. 20, pp. e38018-e38018
Open Access | Times Cited: 4
Bone Loss in Diabetes Mellitus: Diaporosis
Krisztina Kupai, Hsu Lin Kang, Anikó Pósa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7269-7269
Open Access | Times Cited: 4
Global research trends on DPP-4 inhibitors and cardiovascular outcomes a comprehensive bibliometric analysis
Ehsan Amini‐Salehi, Maryam Hasanpour, Abdulhadi Alotaibi, et al.
Annals of Medicine and Surgery (2025) Vol. 87, Iss. 4, pp. 2133-2148
Open Access
Double Diabetes: A Converging Metabolic and Autoimmune Disorder Redefining the Classification and Management of Diabetes
Rajeev Kumar Chaudhary, O. Ali, Amrendra Kumar, et al.
Cureus (2025)
Open Access
Design and Biosynthesis of Ornithine 8-Containing Semaglutide Variants with a Click Chemistry-Modifiable Position 26
Yanli Xu, Oscar P. Kuipers
ACS Synthetic Biology (2025)
Closed Access
Glucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics
Abdulbasit Amin, Toyin Mohammed Salman
Journal of Basic and Clinical Physiology and Pharmacology (2025)
Closed Access
Neuroprotective effects of saxagliptin against radiation-induced cognitive impairment: Insights on Akt/CREB/SIRT1/BDNF signaling pathway
Ashrakt H. Abdelhamid, Eman M. Mantawy, Riham S. Said, et al.
Toxicology and Applied Pharmacology (2024) Vol. 489, pp. 116994-116994
Closed Access | Times Cited: 3
Hepatoprotective effects of vildagliptin mitigates lung biochemical and histopathological changes in experimental hepatopulmonary syndrome model in rat
Safwat A. Mangoura, Marwa A Ahmed, Nashwa Hamad, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113254-113254
Closed Access | Times Cited: 3
Linagliptin: A comprehensive profile
Mohamed Fawzi Kabil, Jude Majed Lababidi, Hassan Mohamed El-Said Azzazy
Profiles of drug substances, excipients, and related methodology (2025), pp. 97-123
Closed Access
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives
Elina Khattab, Michaelia Kyriakou, Elena Leonidou, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 134-134
Open Access
Page 1 - Next Page

Scroll to top